The US biotech is facing yet another setback on its journey to proof-of-concept for its proprietary gene editing technology as two pharma firms back out of collaborations in the neurological space.

The French firm’s vorasidenib, obtained via a 2020 deal with Agios, has met the primary endpoint in a pivotal glioma trial, according to interim data, validating its strategic focus on the oncology space.

Rumors have resurfaced that Novartis is looking to shift some of its eye drugs but the Basle-based behemoth tells Scrip it remains committed to in-market products and R&D projects in the ophthalmology space.

Biden Administration releases first list of Part B drugs subject to inflation rebates; others to follow on quarterly basis. Medicare won’t invoice sponsors until 2025, but patients could see coinsurance reductions next month.